EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer

Saiganesh Sriraman iD, Verneri Virtanen iD, Antti Kukkula, Mervi Toriseva, Anni Lumiainen, Gun West, Matti Poutanen, Pekka Taimen, Maria Sundvall iD

The Journal of Pathology · 2025

DOI: 10.1002/path.6468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2025. Verfasst von Saiganesh Sriraman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Unit, Institute of Biomedicine, and FICAN West Cancer Center Laboratory, University of Turku and Turku University Hospital, Turku, Fi…. Hauptthemen laut MEDLINE: Receptors, Androgen, BRCA1 Protein, Prostatic Neoplasms, Antioxidants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Opetushallitus, Instrumentariumin Tiedesäätiö, Suomen Lääketieteen Säätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lethal prostate cancer (PCa) is a genetically heterogeneous disease characterized by evolving androgen receptor (AR) signaling, eventually culminating in castration resistance. The tumor suppressor gene BRCA1 has multiple functions that include secondary processes cooperating with its main function as a caretaker of genomic integrity. BRCA1 is often mutated in breast and ovarian cancer, but BRCA1 mutations are also associated with PCa, although they are less frequently observed. Most PCa patients do not, however, carry BRCA1 mutations, and interestingly, it has been shown that BRCA1 expression is enriched in castration‐resistant PCa. In this study we elucidated the prostate tissue‐specific role of the BRCA1 protein. Although the regulation of DNA damage response genes has been studied in PCa, comprehensive analyses of BRCA1 regulation in the context of androgen signaling are lacking. Our results indicate that BRCA1 is dynamically regulated by AR signaling and that activation of AR via its natural ligand, dihydrotestosterone, represses BRCA1 expression. Our analyses both in vitro and of patient samples and mouse xenografts showed that BRCA1 expression was induced and sustained after androgen deprivation. Moreover, we observed that oxidative stress–related pathways were regulated by BRCA1 in PCa cells and that androgen deprivation therapy–induced activation of BRCA1 supported the function of NRF2, the master regulator of antioxidant defense, and a known interactor of BRCA1. Impaired NRF2 activity, in the absence of BRCA1, decreased growth in a 3D environment. Our findings shed light on the functional role of BRCA1 protein in PCa and suggest that BRCA1 is regulated by the evolving AR signaling state during PCa progression. Thus, AR‐mediated suppression of BRCA1 accumulates oncogenic alterations in the early phases of PCa tumor progression and safeguards from excessive reactive oxygen species (ROS) when upregulated during androgen deprivation therapy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenBRCA1 ProteinProstatic NeoplasmsAntioxidantsMaleHumansAnimalsSignal TransductionCell Line, TumorGene Expression Regulation, NeoplasticOxidative StressMiceDihydrotestosteroneNF-E2-Related Factor 2

Stichwörter der Autor:innen

BRCA1DNA damageNRF2androgen deprivation therapyandrogen receptorcastration‐resistant prostate canceroxidative stress

Substanzen

Receptors, AndrogenBRCA1 ProteinBRCA1 protein, humanAR protein, humanAntioxidantsDihydrotestosteroneNF-E2-Related Factor 2

Autor:innen und Institutionen

  • Cancer Research Unit, Institute of Biomedicine, and FICAN West Cancer Center Laboratory, University of Turku and Turku University Hospital, Turku, Finland.
  • InFLAMES Research Flagship Center, University of Turku and Åbo Akademi University, Turku, Finland.
  • Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, and FICAN West Cancer Center, University of Turku, Turku, Finland.
  • Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  • Department of Pathology, Tyks Laboratories, Turku University Hospital, Turku, Finland.
  • Department of Oncology, Turku University Hospital, Turku, Finland.

ORCID-Profile: Saiganesh Sriraman, Verneri Virtanen, Maria Sundvall

Förderung

  • Opetushallitus
  • Instrumentariumin Tiedesäätiö
  • Suomen Lääketieteen Säätiö
  • Academy of Finland
  • Lounais-Suomen Syöpäyhdistys
  • Syöpäsäätiö
  • Varsinais-Suomen Sairaanhoitopiiri
  • Turun Yliopistosäätiö

Zitieren

APA

Sriraman, S., Virtanen, V., Kukkula, A., Toriseva, M., Lumiainen, A., West, G., Poutanen, M., Taimen, P., & Sundvall, M. (2025). Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer. The Journal of Pathology. https://doi.org/10.1002/path.6468

Vancouver

Sriraman S, Virtanen V, Kukkula A, Toriseva M, Lumiainen A, West G, et al. Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer. The Journal of Pathology. 2025. doi:10.1002/path.6468

BibTeX
@article{Sriraman2025,
  author = {Sriraman, Saiganesh and Virtanen, Verneri and Kukkula, Antti and Toriseva, Mervi and Lumiainen, Anni and West, Gun and Poutanen, Matti and Taimen, Pekka and Sundvall, Maria},
  title = {Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer},
  journal = {The Journal of Pathology},
  year = {2025},
  doi = {10.1002/path.6468}
}
Kostenlos starten →